Why Is BIOHAVEN LTD (BHVN) Stock Moving Today?

Why BHVN stock is down today

Biohaven Ltd stock fell 14.73% to $12.79 on Thursday as the FDA placed a partial clinical hold on its BHV-7000 program for the treatment of epilepsy. The hold paused new enrollment in the trials pending additional nonclinical studies. This regulatory setback has increased uncertainty for the company's development timeline and raised concerns among investors.

What Happened

The FDA's decision to impose a partial clinical hold on Biohaven's BHV-7000 program has triggered a sharp sell-off in the stock. The move comes amid ongoing challenges for the company, including high cash burn and a recent downgrade in its stock rating. Analysts at H.C. Wainwright noted that the clinical hold adds a layer of uncertainty to Biohaven’s development plans. Meanwhile, Raymond James described the impact of the hold as "manageable." Despite these assessments, the stock fell sharply, with some reports noting a 17% decline.

What The Data Shows

Biohaven has experienced a significant price decline over the past eight trading sessions, dropping 16.5% from $15.27 to $12.76. The stock is currently trading within its 52-week range of $7.48 to $18.57. On September 10, the stock printed one fresh 52-week high and nine fresh 52-week lows. The company remains unprofitable, with an earnings per share (EPS) of -4.48 for the trailing twelve months. Its high beta of 3.17 indicates significant volatility relative to the market.

What To Watch

Investors should monitor the company's next steps in response to the FDA's request for additional nonclinical studies. The resumption of enrollment in the BHV-7000 trials will be a key indicator of progress. Additionally, the breadth of coverage and analyst sentiment will remain important factors to track in the coming weeks.